Introduction
PBK/TOPK (PDZ-binding kinase, T-LAK-cell-originated protein kinase) is a serine-threonine kinase that was cloned as an interaction partner with the human tumor suppressor discs-large (hdlg) by yeast two-hybrid screening and as an IL-2 inducible gene in cytotoxic T lymphocytes (Abe et al., 2000; Gaudet et al., 2000) . PBK/TOPK was also identified as a differentially expressed sequence tag in Burkitt's lymphoma cells (Simons-Evelyn et al., 2001) . The murine homologue was cloned as an IL-6-stimulated gene from murine myeloma cells (Cote et al., 2002) . PBK/TOPK mRNA is expressed in various tumor cell lines and in normal testicular and embryonic tissues (Simons-Evelyn et al., 2001) . PBK/TOPK protein is also highly expressed in primary clinical samples from patients with aggressive hematopoietic neoplasms (Nandi et al., 2004) .
PBK/TOPK functions partly as an MAP kinase kinase by phosphorylation of p38 mitogen-activated protein kinase (MAPK) (Abe et al., 2000; Nandi et al., 2004; Ayllo´n and O'Connor, 2007) and is active during mitosis through phosphorylation of residue Thr9 by cyclin B1/Cdk1 (Abe et al., 2000; Gaudet et al., 2000) . During mitosis, PBK/TOPK forms a complex with cyclinB1/Cdk1 on microtubules that promotes cytokinesis through phosphorylation of PRC1 . Additional downstream targets of PBK/TOPK include the MAPKs JNK1 and ERK2, the latter forming a positive feedback loop with PBK/TOPK that may contribute to tumorigenesis in colorectal cancer cells (Oh et al., 2007; Zhu et al., 2007) . Studies of neural progenitor cells indicate that phospho-PBK/TOPK is detected selectively in M-phase cells in association with condensed chromatin (Dougherty et al., 2005) . Cellcycle-specific regulation of PBK/TOPK is mediated partly by transcription factors E2F and CREB/ATF (Nandi and Rapoport, 2006) . Previous studies also suggest a role for PBK/TOPK in cytokinesis and DNA damage sensing and repair through phosphorylation of histone H2AX (Matsumoto et al., 2004; Zykova et al., 2006; Ayllo´n and O'Connor, 2007) .
These studies, which implicate PBK/TOPK in the regulation of mitosis and DNA repair, suggest that it may also have a significant role in cancer development and progression. Indeed PBK/TOPK is overexpressed in breast cancer, and siRNA-mediated reduction of PBK/ TOPK expression suppresses breast cancer cell growth and clonogenicity (Park et al., 2006; Ayllo´n and O'Connor, 2007) . In addition to its role in the MAPK oncogenic signaling pathway, PBK/TOPK has recently been found to be a downstream target of the EWS-FLI1 chimeric fusion protein that is present in 90% of cases of Ewing sarcoma (Herrero-Martin et al., 2009) . We have previously shown that forced expression of a phosphomimetic mutant of PBK/TOPK resulted in loss of DNA damage checkpoint control leading to aneuploidy and suggested that this observation may be due to attenuation of p53 function (Nandi et al., 2007) . In this study we present both biochemical and genetic evidence to show that PBK/TOPK (hereafter referred to as PBK) physically interacts with p53 through its DBD domain and downregulates its function as indicated by modulation of p53-associated targets including p21.
Results

DNA-binding domain of p53 is required for physical interaction with PBK
In earlier work, using a yeast two-hybrid screen, we identified p53 as a potential interacting partner of PBK (Nandi et al., 2007) . We sought to extend biological relevance to this finding and therefore examined the physical interaction between p53 and PBK under physiological conditions. Because both PBK and wildtype p53 are expressed in human colorectal carcinoma HCT116 cells, we used this cell line for co-immunoprecipitation (co-IP) assays and subsequent functional assays. Figure 1a shows that using either an antibody against PBK or an antibody against p53, it was possible to pull down both proteins in the co-IP experiments, whereas control normal serum IgGs did not pull down the protein complexes in either direction. Densitometry measurements found that about 3% of input p53 was pulled down by the PBK antibody, and 2.7% of input PBK was pulled down by the p53 antibody. These reciprocal co-IP experiments established that endogenous wild-type PBK and p53 physically interact in HCT116 cells.
To identify the domain on p53 responsible for this interaction, we transfected HCT116 cells with p3xflag-PBK in combination with a plasmid encoding either the full-length or one of a series of deletion mutants of p53 and performed co-IP assays (Figure 1b) . Figure 1d shows that full-length p53 and all p53 mutants that contained the DBD domain could co-immunoprecipitate with PBK, but EGFP-p53-mt3, the p53 mutant in which the DBD domain was deleted, did not coimmunoprecipitate with PBK. However, EGFP-p53-DBD, which contained only the DBD domain of p53, co-immunoprecipitated with PBK ( Figure 1d ). Western blot analysis also showed that all the p53 deletion mutants were strongly expressed at the protein level ( Figure 1c ). These data suggested that the DBD domain of p53 was both necessary and sufficient to mediate the protein-protein interaction between p53 and PBK in HCT116 cells.
To confirm these co-IP results, we performed a yeast two-hybrid assay using bait plasmid pGBKT7-PBK and prey constructs expressing either the full-length or the same deletion mutants of p53 that were used in the interaction domain mapping studies by co-IP. As shown in Figure 2a, (c) A western blot shows that strong protein expression was achieved for wild-type p53 and each of the p53 deletion mutants that were used for the co-IP mapping experiment. (d) Mapping region(s) of p53 that interact with PBK by examining interaction in extracts of co-transfected HCT116 cells. HCT116 cells were co-transfected with p3xflag-PBK and full-length or a deletion construct of p53. Western blot analysis of GFP immunoprecipitation showed that the DBD domain of p53 was necessary and sufficient to mediate protein-protein interaction between p53 and PBK.
PBK/TOPK and p53 functional interactions F Hu et al pGADT7-p53-mt3, in which the DBD domain was deleted. Thus, the yeast two-hybrid experiments confirmed that the DBD domain of p53 was responsible for mediating the p53-PBK interaction.
Because p53 mutations occur more frequently in the DBD domain than any other domain, we investigated whether PBK has relevance to mutation-promoted tumorigenesis by checking whether DBD mutations of p53 could affect PBK binding. We introduced mutations into the prey construct pGADT7-p53-DBD at five 'hotspot' positions (R175H, R248W, R273H, G245S and R282W), and conducted yeast two-hybrid experiments with bait construct pGBKT7-PBK (Soussi et al, 2006) . As shown in Supplementary Figure S1 , none of these mutations abolished binding of PBK.
PBK inhibited p53-mediated transcription in HCT116 cells To begin to clarify the functional significance of the molecular interactions between PBK and p53, we first examined the effect of PBK on p53 activity in reporter gene assays. The p53-mediated transcriptional response was measured by using pp53-TA-luc, in which the expression of the luciferase gene was mediated by two p53-binding fragments (Kern et al., 1991; Komarova et al., 1997) . As shown in Figure 2b , although overexpression of PBK alone had little effect on expression of luciferase activity from this reporter construct when promoted by basal levels of endogenous p53, forced expression of PBK appeared to suppress the transcription induced by ectopically expressed p53 in a dosedependent manner.
PBK knockdown activates p21 expression in HCT116 cells
Because the cyclin-dependent kinase inhibitor p21 is a well-known transcriptional target of p53, we investigated whether PBK could also affect transcription of p21 through its interaction with p53. For these studies, we used a luciferase construct pp21-luc, in which the luciferase gene is controlled by a 2.4 kb DNA fragment that includes the human p21 promoter (el-Deiry et al., 1993) . As shown in Figure 3b , transient PBK knockdown using three PBK-specific RNAis increased the p21 promoter activity by about 3-to 4-fold (Po0.01). Using HCT116 cells that were transiently transfected in parallel to those depicted in panel b, we also showed a 2-to 3-fold increase in p21 mRNA expression by qPCR (panel 3c). Western blotting confirmed that the three PBK RNAis (RNAi1, RNAi2 and RNAi3) all suppressed PBK protein expression (panel 3d). To show specificity of this PBK RNAi effect, we used RNAi2 to study whether knockdown of PBK expression would stimulate the promoter function of two genes that are unrelated to the p53 pathway (STAT3 and DR1) and found no effect (panels 3e and f). To further test the effect of PBK knockdown on the expression of p21 at the protein level, we conducted immunoblotting assays using the stable PBK knockdown cell line HCT116-shPBK1 and the control cell line HCT116-RS (Figure 3a ). In the PBK knockdown cells, the p21 level was significantly elevated compared with that in the control cell line. However, the level of p53 protein expression did not change, suggesting that modulation of p53 activity by PBK, rather than a change in p53 level, mainly affected the expression of p21. To further investigate whether p53 is involved in the activation of p21 by PBK knockdown, we treated both cell lines with doxorubicin, a strong p53 activator. The data in 1. pGBKT7-PBK + pGADT7-p53-wt; 2. pGBKT7-PBK + pGADT7-p53-mt1; 3. pGBKT7-PBK + pGADT7-p53-mt2; 4. pGBKT7-PBK + pGADT7-p53-mt3; 5. pGBKT7-PBK + pGADT7-p53-DBD; 6. pGBKT7 + pGADT7-p53-DBD; 7. pGBKT7 + pGADT7-p53-mt3; 8. pGBKT7 + pGADT7-p53-mt2; 9. pGBKT7 + pGADT7-p53-mt1; 10.pGBKT7 + pGADT7-p53-wt.
p3xflag-PBK (μg) pEGFP-p53-wt (0.5 μg) pp53-TA-luc (0.5 μg) Bait construct pGBKT7-PBK and prey construct expressing fulllength or deletion mutants were co-transformed into AH109 strain yeast cells, transformants were plated on -His/-Leu/-Trp triple dropout plates and incubated at 25 1C for 7 days. Colonies appeared wherever a prey construct that contained the DBD domain of p53 was co-transformed into the host cells. Control experiments co-transforming yeast cells with empty bait vector pGBKT7 and each of the prey constructs were performed to exclude false-positive interactions. All p53 fragments contained in the prey constructs were the same as those contained in the mammalian expression constructs used for the co-IP experiments. (b) PBK inhibits p53-mediated transcription in a dose-dependent manner. HCT116 cells grown in 12-well plates were co-transfected with 0.5 mg pEGFP-p53-wt or pEGFP-N1 vector in combination with 0.5 mg pp53-TA-luc and increasing amount of p3xflag-PBK as indicated. p3xflag-cmv-7.1 plasmid was used to balance total amount of DNA transfected in each well. After 24 h, cell extracts were prepared and luciferase activities were quantified. In all the experiments, firefly luciferase activity was normalized against total protein in the same sample and expressed as mean ± s.d. of triplicates from a representative experiment. (c) Cell extract from a parallel transfection with panel (b) was blotted for analysis of PBK and p53 expression; b-actin was blotted for loading control.
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F Hu et al Figure 3a show that, in the presence of 1 mM doxorubicin, p53 levels increased similarly in both cell lines. However, the p21 level was further increased in the PBK knockdown cells compared with the wild-type HCT116 cells. These data are consistent with a model of PBK inhibition of p53 function.
PBK modulation of p21 expression is dependent on p53
To show that the observed modulation of p21 expression by PBK was dependent on p53 function, we examined the effect of PBK knockdown (using RNAi2) on p21 expression in the presence and absence of p53. For these studies, we obtained stable lines derived from HCT116 cells that carried homozygous (HCT116 p53À/À) or heterozygous (HCT116 p53 þ /À) deletions of the p53 gene. As shown in Figure 4a , PBK knockdown had no effect on p21 reporter activity in the HCT116 p53À/À cell line whereas p21 reporter activity significantly increased in the p53 þ / þ line as observed before. The heterozygous HCT116 p53 þ /À cell line appeared to show an intermediate effect. A similar pattern was observed when p21 mRNA expression was measured by qPCR. As shown in Figure 4b , PBK knockdown had no effect on the residual p21 mRNA level in the HCT116 p53À/À cells, induced a minor increase in p21 mRNA expression in the HCT116 p53 þ /À cells and nearly doubled the level of p21 mRNA expression by qPCR in the HCT116 p53 þ / þ cells. One possible mechanism whereby PBK could downregulate p53 transcriptional function would be interference with p53-DNA binding. To test this possibility, we performed a chromatin immunoprecipitation (ChIP) assay was performed. As shown in Figure 4d , overexpression of PBK decreased recruitment of p53 by the p21 promoter in HCT116 cells that were transiently transfected with p3xflag-PBK. 
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Phenotypic studies of PBK knockdown cell lines Having shown in HCT116 cells that PBK knockdown could upregulate p53 function and p21 expression, we hypothesized that stable PBK knockdown cell lines would show predictable phenotypic changes regarding proliferation, cell-cycle progression and sensitivity to apoptosis. First, we compared the cell growth curve of the PBK knockdown stable cell line HCT116-shPBK1 to the growth of control HCT116-RS cells. As expected, HCT116-shPBK1 cells showed a significantly elongated population doubling time (Po0.0001) and slower growth (Figures 5a-c) . Second, cell-cycle progression was examined after treatment of both the stable PBK knockdown HCT116-shPBK1 cell line and the parental HCT116 cell line with the genotoxin doxorubicin or dimethyl sulfoxide (DMSO). As shown in Figure 6a , in the PBK knockdown cell line HCT116-shPBK1 the %G 2 /M cells increased from 10.5 to 54.8% after exposure to 1 mM doxorubicin. The %G 2 /M cells increased from 16 to 34% in the presence of DMSO diluent alone, suggesting that PBK knockdown could lead to cell-cycle arrest in the absence of genotoxins. Similar results were obtained after treatment of a second stable PBK knockdown cell line derived from MCF-7 breast cancer cells (Supplementary Figure S2) . A separate HCT116-shPBK2 stable cell line derived using a second shRNA construct also showed accumulation of G 2 /M cells when compared with HCT116-V-RS cells carrying a scrambled, nonspecific shRNA construct (Supplementary Figure S3) . These phenotypic changes correlated to DMSO/doxorubicin-induced increases in p53 protein level, as shown by western blotting, that were exaggerated in the PBK knockdown lines as compared with the control cell lines (Figure 6c) . Finally, as shown in Figures 6d and e, apoptosis assayed by Trypan blue staining was significantly increased in both the HCT116 and MCF-7 stable PBK knockdown cell lines as compared with the control cell lines after exposure to either DMSO or doxorubicin. Similar results were obtained by Annexin V staining (data not shown).
Gene microarray studies
To identify other genes that might be targets of PBK, we treated HCT116-RS and HCT116-shPBK1 cells with 1 mM doxorubicin for 24 h. Cellular RNA was extracted from cells and subjected to microarray analysis using the Affymetrix (Santa Clara, CA, USA) GeneChip Human Gene 1.0 ST Array. Relative to the empty-vector cell line, the stable knockdown cell line showed about a 2.6-fold decrease in PBK mRNA. Expression levels of at least nine p53 target genes involved in cell-cycle regulation and/or apoptosis were also significantly altered by PBK knockdown. Among these were p21 (Bunz et al., 1998; Wendt et al., 2006) , DUSP1 (Li et al., 2003) PBK/TOPK and p53 functional interactions F Hu et al (Pohl et al., 1999) , FAS (Mu¨ller et al., 1998; Pohl et al., 1999) , CASP10 (Rikhof et al., 2003) (all upregulated), and Bcl-xL (Bartke et al., 2001) , which was downregulated. G2E3 (Brooks et al., 2007 (Brooks et al., , 2008 , a newly characterized gene involved in G 2 /M cell-cycle progression, was found to be suppressed by PBK knockdown, but its association to p53 is unknown. We validated the microarray analysis results for all nine genes by qRT-PCR (see Table 1 and Supplementary Figure S4 ).
Discussion
Several lines of evidence suggest that the serinethreonine kinase PBK may contribute to tumor development and growth. Among these is that PBK was cloned on the basis of a yeast two-hybrid screen of HeLa cells using the hDlg tumor suppressor protein as bait (Gaudet et al., 2000) . The hDlg tumor suppressor, the human homologue of the Drosophila Discs-large protein, interacts with multiple oncogenic proteins including the adenomatous polyposis coli tumor suppressor protein, the human papillomavirus E6 transforming protein and the adenovirus E4 transforming protein 9ORF1 (Matsumine et al., 1996; Kiyono et al., 1997; Lee et al., 1997) .
In this study we show that PBK also interacts with p53, another key tumor suppressor protein. Our model system was HCT116 human colorectal cancer cells as this line is known to express wild-type p53 and therefore could provide more physiologic conditions for studying protein-protein interactions involving p53. Using both reciprocal co-IP experiments of unmodified PBK and p53 and yeast two-hybrid analysis, we showed that PBK physically interacts with p53 specifically through its DNA-binding domain (DBD). The DBD or central domain of p53 contains about 80% of the p53 mutations that occur in cancer cells (Soussi, 2007) . It is also the critical interaction site for several important proteins that regulate p53 function including the ASPP proteins which shift p53 function toward apoptosis induction through upregulation of proapoptotic proteins Bax, PUMA and PIG3 (Patel et al., 2008) . The antiapoptotic proteins BCL-x L and Bcl2 also interact with p53 through binding to the DBD domain with Bcl2 binding exclusively to wild-type p53 (Tomita et al., 2006; Sot et al., 2007) .
To test whether PBK binding to wild-type p53 could modulate its transcriptional function, we studied the effect of PBK on expression of the cell-cycle inhibitor p21, a key transcriptional target for p53. Using transient co-transfection assays in HCT116 cells, we observed that PBK knockdown by three PBKRNAis led to a significant increase in luciferase activity from a p21 promoter-luciferase construct. In addition, PBK knockdown by RNAi led to a significant increase in p21 mRNA by quantitative PCR analysis. A similar result was obtained at the p21 protein level using the stable PBK knockdown cell line HCT116-shPBK1. Under conditions of genotoxic damage by doxorubicin, p21 levels increased in the stable PBK knockdown cells (HCT116-shPBK1) in response to p53 induction, to a much greater degree than in the stable empty-vector control cell line (HCT116-RS). Knockdown of PBK expression had no effect on the promoter functions of two genes that are not known to be part of the p53 pathways (STAT3 and DR1). These PBK/TOPK and p53 functional interactions F Hu et al data suggest that PBK inhibits p53 transactivation of p21 expression, which is partially released by PBK knockdown. Furthermore, overexpression of PBK led to interference with p53 binding to the p21 promoter region by ChIP assays. These data are consistent with the model that PBK interacts with the DBD of p53 and thereby inhibits p53 binding to target gene promoter sequences.
Because of the high prevalence of p53 mutations in cancer, we also studied whether PBK could bind to certain p53 tumor mutants. These Y2H studies showed that PBK binding was retained. The functional consequences of this interaction could be different than the functional consequences of PBK binding to wild-type p53. Indeed, BclxL binds to both wild-type and mutant p53 proteins (although with reduced affinity) yet only the interaction with wild-type p53 results in the conformational change in BclxL, which leads to proapoptotic activity (Hagn et al., 2010) . In addition, mutant p53 proteins show gain-of-function properties including association with the nuclear matrix, formation of transcriptionally active protein complexes and sequestration of proapoptotic proteins (reviewed in Strano et al., 2007) . Through binding to p53 mutants, PBK could modulate these oncogenic functions.
To strengthen the model that PBK modulation of p21 expression depends on interaction with p53, we examined the effect of PBK knockdown in HCT116 cells lines that were heterozygous or homozygous for p53 gene deletions. These studies confirmed that PBK knockdown had no effect on p21 expression in the p53 knockout line (HCT116-p53À/À), significantly increased p21 expression in the wild-type (p53 þ / þ ) line and showed an intermediate response in the heterozygous 
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Figure 6 Phenotypic changes in stable PBK knockdown cell lines regarding cell-cycle distribution and apoptosis. Representative results from three independent experiments looking at the effects of PBK knockdown on cell-cycle distribution are shown. (a, b) A total of 2 Â 10 6 HCT116-RS and HCT116-shPBK1 cells were plated in a 60 mm cell culture dish. The following day cells were treated with DMSO or 1 mM doxorubicin for 24 h, collected, stained with PI and subjected to FCM analysis for cell-cycle distribution. A significant increase in %G 2 /M cells is apparent for the HCT116-shPBK1 stable knockdown cell line under both the conditions. (c) Cells treated in parallel with those in panels a and b and Supplementary Figure S2 were lysed and subjected to western blot analysis for expression of PBK and p53. b-Actin was blotted as a loading control. (d) A total of 1 Â 10 6 cells from the HCT116-RS and HCT116-shPBK1 stable lines, and (e) 1 Â 10 6 MCF-7-RS and MCF-7-shPBK1 cells were plated in six-well plates. Cells were serum starved for 24 h the following day. The medium was then changed to medium that contained 10% fetal bovine serum and 1 mM doxorubicin or solvent DMSO. After 24 h, cells were collected and stained with Trypan blue. Live and dead cells were counted using a hemocytometer. Average and s.d. from three independent experiments are shown, indicating that for both the HCT116-shPBK1 and MCF-7-shPBK1 stable cell lines, PBK knockdown augments apoptosis. (f) MCF-7 cells treated in parallel with those in panels c and e were lysed and subjected to western blot assay for PBK and p53 to show downregulation of PBK. b-Actin was blotted for loading control. A comparable blot for the stable HCT116-shPBK1 cell line is depicted in Figure 5d . line (p53 þ /À) perhaps reflecting a p53 dose-dependent effect.
These findings suggest that PBK overexpression may promote tumor cell survival and resistance to chemotherapy-induced apoptosis through suppression of p21 expression and p53 function. One prediction of this model is that PBK knockdown in tumor cells should decrease proliferation and tumorigenicity through increased p21 expression and p53 function. Indeed three stable PBK knockdown cell lines showed accumulation in the G 2 /M phase of the cell cycle and increased apoptosis after exposure to DMSO or doxorubicin when compared with control lines that carried empty vectors or nonspecific shRNAs.
These findings complement earlier work showing that ectopic expression of a phosphomimetic mutant of PBK in HT1080 fibrosarcoma cells (known to carry wild-type p53 genes) attenuates G 2 /M checkpoint control during doxorubicin treatment (Nandi et al., 2007) . Our findings also agree with previous studies showing that reduced PBK expression in MCF-7 breast cancer cells led to slower growth and reduced clonogenicity in soft agar assays (Ayllo´n and O'Connor, 2007) . These investigators also showed that MCF-7 tumor cells with knocked down PBK expression exhibited decreased survival following DNA damage from UV or chemotherapeutic agents as well as impaired generation of phosphorylated H2AX (g-H2AX), an early response to double-strand DNA breaks (Ayllo´n and O'Connor, 2007) . Other investigators showed that knocked down expression of PBK in HCT116 colorectal carcinoma cells decreased tumorigenicity .
The gene microarray studies reinforced the functional relationship between PBK and p53 by identifying at least seven p53 target genes (in addition to p21) involved in regulation of cell cycle and apoptosis and whose expression levels were modulated by PBK knockdown.
This article adds to the growing recognition that PBK is an oncoprotein and should be considered a valid target for the development of novel antineoplastic therapeutics. Furthermore, based on its restricted pattern of expression to tumor cells, testis, embryonic tissues and adult progenitor cells (Simons-Evelyn et al., 2001; Dougherty et al., 2005; Park et al., 2006) , PBK may be considered a novel cancer/testis antigen that may also have a role in maintenance of tumor stem cells. Future studies are warranted to identify small molecular inhibitors of PBK and test them for the ability to sensitize tumor cells to chemotherapy-induced apoptosis and growth suppression.
Materials and methods
Antibodies
Primary antibodies: rabbit anti-PBK, rabbit anti-p53 and a mouse monoclonal antibody against p21 were purchased from Cell Signaling Technology (Danvers, MA, USA); rabbit anti-bactin, rabbit anti-GFP polyclonal antibodies and anti-FLAG M2 monoclonal antibody were purchased from Sigma-Aldrich (St Louis, MO, USA). Secondary antibodies: both horseradishperoxidase-conjugated donkey anti-rabbit IgG and horseradishperoxidase-conjugated sheep anti-mouse IgG were purchased from GE Healthcare Amersham (Piscataway, NJ, USA).
Cloning vectors
The mammalian expression vector p3xflag-cmv-7.1 was purchased from Sigma-Aldrich. The mammalian expression vector pEGFP-N1 and yeast two-hybrid vectors pGBKT7 and pGADT7 were purchased from Clontech (Mountain View, CA, USA).
Gene microarray studies
To identify other genes and pathways that might be targets of PBK, we treated HCT116-RS and HCT116-shPBK cells with 1 mM doxorubicin for 24 h. Cellular RNA was extracted from cells and subjected to microarray analysis. Labeled cRNA was hybridized onto Affymetrix GeneChip Human Gene 1.0 ST Array. Further details on microarray procedures and analysis can be found in Supplementary Methods.
Plasmid constructions
For PCR reactions and DNA cloning, a high-fidelity DNA polymerase enzyme Platinum Taq DNA Polymerase High Fidelity and 100 mM dNTP set were used (Invitrogen, San Diego, CA, USA). Restriction enzymes BamHI, HindIII, NheI, et al. (2001) shPBK/control ratio and P-value for microarray analysis were calculated using the Expression Console software from Affymetrix. shPBK/control ratio for qRT-PCR is fold change as in Supplementary Figure S4 . The reporter construct pp53-TA-luc, in which luciferase expression is under control of two p53-binding fragments, was purchased from Clontech. The p21 promoter reporter construct pp21-luc was a generous gift from Bert Vogelstein at Johns Hopkins University School of Medicine.
Cell lines, cell culture and transfection studies The HCT116 human colon carcinoma cells were maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum (Quality Biological Inc., Gaithersburg, MD, USA), and 1% penicillin/streptomycin. Cell lines HCT116-p53À/À and HCT116-p53 þ /À were generously provided by Dr Vogelstein. MCF-7 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. New stable cell lines obtained after transfection were maintained in the same media supplemented with 2 mg/ml puromycin. RNAis and plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen). PBK Validated Stealth RNAi, Stealth RNAi Negative Control, Dnase I and recombinant RNAseOUT were purchased from Invitrogen. Doxorubicin was purchased from Sigma-Aldrich.
Immunoprecipitation studies For co-IP of endogenous PBK and p53, HCT116 cells grown in a 100 mm Petri dish were lysed in standard radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors. Details of the immunoprecipitation are provided in Supplementary Methods. The immunoprecipitates were eluted by the 2 Â SDS sample buffer and 20% of eluate was resolved by SDS-polyacrylamide gel electrophoresis for western blot analysis.
To identify the p53 domain(s) responsible for proteinprotein interaction between PBK and p53 by co-IP, we generated a mammalian expression construct pEGFP-p53-wt in which full-length p53 cDNA was fused to the N terminus of an EGFP tag. In addition, using PCR, we generated a series of GFP constructs each containing a p53 deletion mutant lacking one or more functional domains. Co-transfections were performed using a plasmid p3xflag-PBK, which encodes a Flag-tagged PBK (see Supplementary Methods for details).
Yeast two-hybrid assay All reagents for the Y2H assay were purchased from Clontech. The assay was performed in accordance with the manufacturer's instructions. The AH109 yeast strain was used for yeast two-hybrid analysis. Bait plasmid pGBKT7-PBK (1 mg) together with prey plasmid (1 mg) were used to transform competent AH109 cells. Transformants were streaked onHis/-Leu/-Trp triple dropout plates and incubated at 25 1C for 7 days (see Supplementary Methods for details).
Quantitative RT-PCR HCT116 cells were transfected with PBK Validated Stealth RNAis and Scrambled RNAi Negative Control. Total cellular RNAs were extracted 48 h after transfection using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNAs were reverse transcribed into cDNA with the Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Quantitative RT-PCR analysis of p21 gene expression was carried out using QuantiTect SYBR Green RT-PCR Kit from Qiagen on an ABI 7900HT Fast Real-Time PCR System, according to the manufacturer's instructions (see Supplementary Methods for primer details). To verify the results of the qPCR measurements, we run the PCR products on 3% agarose gels and sequenced after purification.
Western blot analysis
For western blot analysis, 20 mg of protein was fractionated on NuPAGE 4-12% Bis-Tris Gels (Invitrogen), and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). The membranes were blocked with 5% fat-free milk for 1 h at room temperature and then probed with 1:1000 dilution of primary antibody overnight at 4 1C, followed by incubation with 1:10 000 dilution of horseradish-peroxidaselinked secondary antibody. The antibody-antigen complex was visualized by ECL chemiluminescence (GE Healthcare Amersham) and developed on Kodak Biomax Light Film (Sigma-Aldrich). Membranes were reblotted with anti-b-actin antibody to control for uneven protein loading.
Luciferase assay HCT116 cells were seeded in 12-well plates and grown to 80% confluence. On the following day, cells were transfected with plasmids as indicated. In each case, correspondent empty vectors were used to balance the amount of plasmids used in each transfection. Cell lysates were collected 48 h after transfection. Luciferase activity was measured with the DualLuciferase Reporter Assay System (Promega) on a Mithras LB 940 Multimode Reader (Berthold Technologies, Wildbad, Germany). The protein content in each sample was measured and used to normalize the luciferase activity.
Establishment of PBK knockdown stable cell lines
To establish the stable PBK knockdown cell lines HCT116-shPBK1, HCT116-shPBK2 and MCF-7-shPBK1, we transfected 5 mg pRS-shPBK1 or pRS-shPBK2 into HCT116 or MCF-7 cells with the Lipofectamine 2000 transfection reagent. Starting 24 h after transfection, cells were selected in 2 mg/ml puromycin (Sigma-Aldrich) for 3 weeks. Control cell lines HCT116-RS, HCT116-V-RS and MCF-7-RS were established by transfecting cells with 5 mg pRS-vector or pGFP-V-RS that expresses a 29-mer scrambled shRNA and selected under the same conditions. Puromycin-resistant cells were assayed for protein expression by immunoblotting with a monoclonal antibody against PBK (Cell Signaling Technology).
Cell growth studies using PBK knockdown stable cell line HCT116-shPBK1 A total of 20 000 wild-type HCT116-RS cells or PBK knockdown HCT116-shPBK1 cells were seeded on each 60 mm dish at day 0. Cells in four dishes of each cell line were counted using a hemocytometer every 24 h for 5 days.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed using the EZ ChIP kit (Millipore, Billerica, MA, USA). Briefly, HCT116 cells were lysed, sonicated and exposed to rabbit antip53 antibody (Cell Signaling Technology) or the same amount of control IgG. Details of the procedure are provided in Supplementary Methods.
Flow cytometry analysis
For fluorescence-activated cell sorting analysis, collected cells were fixed in 80% ice-cold ethanol for 1 h. Cells were then rehydrated in phosphate-buffered saline, treated with the propidium iodide staining solution (50 mg/ml propidium iodide and 0.5 mg/ml RNaseA in phosphate-buffered saline) for 30 min at room temperature and analyzed using an FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
Statistical analysis
Data are presented as means±s.d. The Student's t-test was used for statistical analysis, with Po0.05 defined as statistically significant. Longitudinal regression analysis was conducted to compare the growth rates between the wild-type and PBK knockdown cells.
